Ascletis Pharma Inc. (Ascletis) disclosed in its latest Next Day Disclosure Return (27 October 2026) that it repurchased an additional 100,000 ordinary shares on 27 October at prices between HKD 5.355 and HKD 5.445 per share, for a total consideration of HKD 0.54 million.

Key data points

1. Share capital position • Issued shares (excluding treasury shares) stood unchanged at 1.05 billion as of 27 October 2026. • Treasury shares totalled 5.78 million, leaving the overall share count at 1.06 billion.

2. Ongoing share repurchase programme • Between 30 June and 27 October 2026, Ascletis bought back 5.10 million shares for cancellation. • Cumulative outlay over the period amounted to approximately HKD 37.87 million, implying an average repurchase cost of about HKD 7.44 per share. • Purchase prices ranged from a high of HKD 11.53 on 7 July to HKD 5.36–5.45 on 27 October, reflecting market price movements during the four-month span. • The repurchased shares represent 0.48% of Ascletis’ issued share capital (excluding treasury shares) as at the mandate date of 29 June 2026.

3. Repurchase authority and restrictions • The current mandate, approved on 29 June 2026, permits the company to repurchase up to 106.14 million shares. • Following the latest transaction, 101.04 million shares remain available under the mandate. • In line with Hong Kong Listing Rules, Ascletis is subject to a moratorium on new share issues or sales/transfer of treasury shares until 26 November 2026.

The company confirmed that all buy-backs were executed on the Hong Kong Stock Exchange in compliance with the exchange’s Main Board Rules, with no material changes to the repurchase explanatory statement dated 8 June 2026.